HMG- CoA reduktase hæmmere, fibrater og ciclosporin). • Cubicin bør ikke administreres til patienter, som tager andre lægemidler associeret med myopati, medmindre fordelen for patienten anses for at opveje risikoen. • Patienterne bør undersøges regelmæssigt under behandlingen for alle tegn og symptomer, der kan tyde på myopati. • Alle patienter, der udvikler uforklarlige muskelsmerter, - ømhed, - svaghed eller - kramper bør have overvåget CPK- værdierne hver anden dag.
HMG-CoA reductase inhibitors, fibrates and ciclosporin). • Cubicin should not be administered to patients who are taking other medications associated with myopathy unless it is considered that the benefit to the patient outweighs the risk. • Patients should be reviewed regularly while on therapy for any signs or symptoms that might represent myopathy. • Any patient that develops unexplained muscle pain, tenderness, weakness or cramps should have CPK levels monitored every 2 days.